Article summary
This multisite open-label study (n=69) examined intravenous racemic ketamine (35 mg/70 kg) given in three infusions to adults with treatment-resistant depression, finding that depressive symptoms improved and 54% reached remission. Ketamine was linked to widespread changes in metabolites involved in energy production, neurotransmitters and stress hormones, but no metabolite reliably predicted symptom improvement.
Continue to the original publication for the complete article.